TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02914158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Study: NCT03844555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: 120mg oral single dose
Study: NCT02422706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole(MTZ)
Description: Metronidazole 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 20 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: KLacid twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: KLacid twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Tavanic. Tavacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxicycline
Description: Vibramycin 100 mg twice daily
Study: NCT02753166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
Study: NCT02398916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Study: NCT01456286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin
Description: two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sapropterin
Description: two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
Study: NCT01703078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol once daily for two consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol once daily for two consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol once daily for two consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol once daily for two consecutive days
Study: NCT01131988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Capsules
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Capsules
Description: Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
Study: NCT05360927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study: NCT04564846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORMD-0801
Description: 8 mg capsules of ORMD-0801 (Oral Insulin)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (Fish Oil)
Study: NCT02574403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: eculizumab discontinuation
Study: NCT02216669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTP348
Description: Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
Study: NCT04086017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Description: Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
Study: NCT01766050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belatacept
Study: NCT03029806

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aldosterone response to AngII LS
Description: Change in aldosterone from baseline to after Ang II infusion on a LS diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aldosterone response to AngII LS
Description: Change in aldosterone from baseline to after Ang II infusion on a LS diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aldosterone response to AngII LS
Description: Change in aldosterone from baseline to after Ang II infusion on a LS diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aldosterone response to AngII LS
Description: Change in aldosterone from baseline to after Ang II infusion on a LS diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Renal blood flow response to salt
Description: Change in renal blood flow: High salt to low salt diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Renal blood flow response to salt
Description: Change in renal blood flow: High salt to low salt diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Renal blood flow response to salt
Description: Change in renal blood flow: High salt to low salt diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Renal blood flow response to salt
Description: Change in renal blood flow: High salt to low salt diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vascular Stiffness
Description: Change in vascular stiffness, baseline compared to AngII

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Stiffness
Description: Change in vascular stiffness, baseline compared to AngII

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vascular Stiffness
Description: Change in vascular stiffness, baseline compared to AngII

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vascular Stiffness
Description: Change in vascular stiffness, baseline compared to AngII
Study: NCT04277949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erbium:YAG
Description: Treatment with Erbium:YAG laser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV endonuclease from Micrococcus luteus
Description: Application of topical DNA repair enzymes
Study: NCT03496493

Intervention type: DEVICE
Intervention: All patients
Description: Peripheral arterial oxygen saturation recording with both study devices
Study: NCT01704027

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost intensity-modulated arctherapy
Description: Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~* Pelvis : 55,5 Gy (1,85 Gy/fr)~* Seminal vesicles : 66 Gy (2,2 Gy/fr)~* Prostate : 72 Gy (2,4 Gy/fr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Description: Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
Study: NCT03212326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]
Description: Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
Study: NCT02134223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT
Study: NCT02813629

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS plus PES
Description: transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability.
Study: NCT04191473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMR-P
Description: After submucosal injection, we use ESD knife or the tip of the entrapment device to loop around the lesion, and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CEMR
Description: A liquid pad was formed by injecting 0.9% normal saline with meilan solution into submucosa,and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
Study: NCT03801473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robot assisted gait therapy
Description: The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
Study: NCT02170818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Workshop on Speaking-Up
Description: Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unrelated Education (CPR)
Description: Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
Study: NCT01321151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
Study: NCT04483700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study: NCT00791063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F ML-10
Description: Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
Study: NCT00291616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha2a
Description: 180 microgram s.c. injection weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin alpha1 & Pegylated Interferon-alpha2a
Description: Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
Study: NCT03111303

Intervention type: DEVICE
Intervention: mechanical ventilation
Description: Connection to mechanical ventilator

Intervention type: DEVICE
Intervention: mechanical ventilation
Description: Connection to mechanical ventilator
Study: NCT02763306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Treatment with dermal cooling system.
Study: NCT02893566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mi Band Step Challenge
Study: NCT04921202

Intervention type: OTHER
Intervention: Metabolic syndrome and meniscus injuries
Description: Metabolic syndrome
Study: NCT04483700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study: NCT01575028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The local anesthetic at the incision sites will be injected by the surgeon.
Study: NCT01319708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mild ovarian stimulation
Description: 100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ovarian stimulation
Description: 300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
Study: NCT00002682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline Hydrochloride
Study: NCT03525444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-445/TEZ/IVA
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
Study: NCT03033277

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transplantation
Description: Intraovarian injection of placebo through vagina under the guidance of ultrasonic.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs transplantation
Description: Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
Study: NCT03460886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipsilesional stimulation
Description: anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipsilesional stimulation
Description: anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralesional stimulation
Description: anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralesional stimulation
Description: anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: walking on treadmill for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: walking on treadmill for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: walking on treadmill for 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking on treadmill
Description: walking on treadmill for 10 minutes
Study: NCT03270943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFY
Description: Mindful Self-Compassion course for teens

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLG
Description: Healthy Lifestyles course for teens
Study: NCT02973100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03285724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Artificial ePTFE Chords
Description: The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
Study: NCT01590030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic dermoid cystectomy
Description: Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic dermoid cystectomy
Description: Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
Study: NCT00055302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimidex 1 mg
Description: Arimidex (anastrozole) 1mg once daily by mouth
Study: NCT04032067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GV1001 placebo
Description: 0.9 % Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proscar placebo
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proscar placebo
Description: PO
Study: NCT02861612

Intervention type: PROCEDURE
Intervention: Nerve Transfer Surgery
Description: Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
Study: NCT04483700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study: NCT00214279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Description: prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus